Behaviour of (-)-deprenyl and its analogues

  • K. Magyar
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


A number of new deprenyl analogues were synthesized during the last decades and structure-activity relationship studies were carried out with the compounds. Among these derivatives U-1424 [N-methyl-N-pro-pargyl-(2-furyl-l-methyl)-ethyl ammonium] and J-508 [N-methyl-N-pro-pargyl-(l-indanyl) ammonium] preserved the selectivity to MAO-B, but the former is slightly less potent inhibitor of the enzyme, while J-508 is more effective than the parent compound. The studies led us to the conclusion that, in the case of a selective and irreversible inhibitor, it is not a proper aim to search for a more potent inhibitor than deprenyl. Nevertheless, the effects of the new derivatives independent of the enzyme inhibitory potency can be beneficial. In this respect p-fluoro-deprenyl (PFD) seems to be promising.


Inhibitory Potency Corpus Striatum Phenyl Ethyl Amine Ethyl Ammonium Time Related Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brodie BB, Cho AK, Gessa GL (1970) Possible role of p-hydroxynorephedrine in the depletion of norepinephrine induced by d-amphetamine and in tolerance to this drug. In: Costa E, Garatini S (ed) Amphetamines and related compounds. Raven Press, New York, pp 217–230.Google Scholar
  2. Ekstedt B, Magyar K, Knoll J (1978) Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?. Biochem Pharmacol 28: 919–923.CrossRefGoogle Scholar
  3. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184: 119–126.PubMedCrossRefGoogle Scholar
  4. Goldstein M, Anagnoste B (1965) The conversion in vivo of d-amphetamine to (+)-p-hydroxy-norephedrine. Biochim Biophys Acta 107: 166–168.PubMedCrossRefGoogle Scholar
  5. Heinonen EH, Myllyla, V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M, Savijärvi M, Kotila M, Rinne UK (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126: 93–99.Google Scholar
  6. Knoll J (1983) (-)-Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand [Suppl] 95: 57–80.CrossRefGoogle Scholar
  7. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandier M (eds) Monoamine oxidases. New vistas. Raven Press, New York, pp 393–408 (Adv Biochem Psychopharmacol, vol 5).Google Scholar
  8. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpro-pinylamine (E-250), and new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154–164.PubMedGoogle Scholar
  9. Knoll J, Ecseri Z, Magyar K, Sátory é (1978) Novel (-)-deprenyl — derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 27: 1739–1747.PubMedCrossRefGoogle Scholar
  10. Langston JW (1980) Selegiline as neuroprotectiv therapy in Parkinson’s disease: concepts and controversies. Neurology 40[Suppl 3]: 61–66.Google Scholar
  11. Magyar K (1991) Neuroprotective effect of deprenyl and p-fluor-deprenyl. In: Fazekas F, Schmutzharol E, Zeiler K (eds) Paneuropean Society of Neurology, Second Congress, Vienna, p 26 (Abstract).Google Scholar
  12. Magyar K, Szüts T (1982) The fate of (-)-deprenyl in the body. Preclinical studies. In: Proceedings of the International Symposium on (-)-deprenyl, Jumex, Szombathely, Hungary, 1982. Chinoin, Budapest, pp 25-31.Google Scholar
  13. Magyar K, Ecseri Z, Bernáth G, Sátory É, Knoll J (1980) Structure-activity relationship of selective inhibitors of MAO-B. In: Magyar K (ed) Monoamine oxidases and their selective inhibition. Pergamon Press, Budapest, pp 11–21.Google Scholar
  14. Magyar K, Tóthfalusi L (1984) Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 36: 373–384.PubMedGoogle Scholar
  15. Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Hung 32: 377–387.Google Scholar
  16. Magyar K, Skolnik J, Knoll J (1968) Radiopharmacological analytic studies with deprenyl-14C. In: Leszkowszky GP (ed) V. Conferencia Hungarica pro Therapia et Investigatione in Pharmacologia. Budapest Publ House. Acad Sci, Budapest, pp 103–109.Google Scholar
  17. Reynolds GP, Elsworth JD, Blau K, Sandier M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–554.PubMedGoogle Scholar
  18. Ross SB (1976) Long-term effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br J Pharmacol 58: 521–527.PubMedGoogle Scholar
  19. Snyder SH, Coyle JT (1969) Regional differences in 3H-norepinephrine and 3H-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165: 78–86.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • K. Magyar
    • 1
  1. 1.Department of PharmacodynamicsSemmelweis University of MedicineBudapestHungary

Personalised recommendations